185 related articles for article (PubMed ID: 25572781)
1. Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab.
Sendur MA; Aksoy S; Altundag K
Future Oncol; 2015; 11(1):13-5. PubMed ID: 25572781
[No Abstract] [Full Text] [Related]
2. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity: trastuzumab and cancer survivors.
Patanè S
Int J Cardiol; 2014 Dec; 177(2):554-6. PubMed ID: 25205483
[No Abstract] [Full Text] [Related]
4. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients.
Leemasawat K; Phrommintikul A; Chattipakorn SC; Chattipakorn N
Cell Mol Life Sci; 2020 Apr; 77(8):1571-1589. PubMed ID: 31650186
[TBL] [Abstract][Full Text] [Related]
5. Pertuzumab in HER2-positive breast cancer.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab for the treatment of breast cancer: a safety review.
Gao J; Swain SM
Expert Opin Drug Saf; 2016 Jun; 15(6):853-63. PubMed ID: 26982349
[TBL] [Abstract][Full Text] [Related]
7. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
8. Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.
O'Sullivan CC; Swain SM
Expert Opin Biol Ther; 2013 May; 13(5):779-90. PubMed ID: 23530718
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
10. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
11. Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.
Malenfant SJ; Eckmann KR; Barnett CM
Pharmacotherapy; 2014 Jan; 34(1):60-71. PubMed ID: 23918291
[TBL] [Abstract][Full Text] [Related]
12. [Pertuzumab. Dual strategy for the first-line treatment of metastatic HER2-positive breast cancer].
Bruhn C
Med Monatsschr Pharm; 2013 Jun; 36(6):210-4. PubMed ID: 23814981
[No Abstract] [Full Text] [Related]
13. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
14. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.
Cortés J; Fumoleau P; Bianchi GV; Petrella TM; Gelmon K; Pivot X; Verma S; Albanell J; Conte P; Lluch A; Salvagni S; Servent V; Gianni L; Scaltriti M; Ross GA; Dixon J; Szado T; Baselga J
J Clin Oncol; 2012 May; 30(14):1594-600. PubMed ID: 22393084
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
17. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
18. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
19. Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients.
Aitelhaj M; Lkhouyaali S; Rais G; Mohtaram A; Raissouni S; Ghissassi B; Boutayeb S; Mrabti H; Bensouda Y; Errihani H
BMC Res Notes; 2013 Aug; 6():339. PubMed ID: 23985308
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab for the treatment of metastatic breast cancer.
Langdon SP; Cameron DA
Expert Rev Anticancer Ther; 2013 Aug; 13(8):907-18. PubMed ID: 23984893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]